

Edgar Filing: AVENTIS - Form 425

AVENTIS  
Form 425  
January 28, 2004

Filed by Sanofi-Synthelabo  
Pursuant to Rule 135 and Rule 425(a) under the  
United States Securities Act of 1933, as amended,  
and deemed filed pursuant to Rule 14d-2(b)(2) of the  
United States Securities Exchange Act of 1934, as amended

Subject Company: Aventis  
Commission File No. 001-10378  
Date: January 28, 2004

ON JANUARY 28, 2004, THE FOLLOWING ADVERTISEMENT WAS PUBLISHED ON  
BEHALF OF SANOFI-SYNTHELABO IN THE INTERNATIONAL HERALD TRIBUNE EUROPEAN  
EDITION.

\* \* \* \*

WE REFUSE TO ACCEPT THAT THERE ISN'T  
A FASTER WAY TO FIND A MEDICINE  
FOR TOMMY'S DISEASE.

[Image of child in hospital bed]

Who is going to tell Tommy that the medicine that could cure him won't be ready  
for 20 years? You? No.

No one. Joining forces with Aventis will represent a giant step forward for  
research. We will be able to provide patients with new drugs and innovative  
solutions faster. Together, we will harness our complementary skills to create a  
leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to  
improving healthcare and capable of driving strong, sustainable and profitable  
growth.

SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS  
BECAUSE HEALTH MATTERS

This advertisement does not constitute an offer to sell or an offer to purchase  
any securities

For further information please call: + 33 1 41 33 08 87  
[www.sanofi-synthelabo.com](http://www.sanofi-synthelabo.com)